Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.57 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 8/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532055 | 0.89 | SNCA (0.51) | ALDH1A1KDM4EMAPK1HSD17B10TSHR | |
| SCHEMBL532191 | 0.87 | PIK3CA (0.64) | ALDH1A1KDM4EMAPK1HSD17B10TSHR | |
| SCHEMBL532677 | 0.86 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPK1HSD17B10TSHR | |
| SCHEMBL532676 | 0.81 | PIK3CA (0.79) | ALDH1A1KDM4EMAPK1HSD17B10TSHR | |
| SCHEMBL533102 | 0.79 | PIK3CA (0.58) | ALDH1A1KDM4EMAPK1HSD17B10TSHR | |
| SCHEMBL532198 | 0.78 | PIK3CA (0.61) | ALDH1A1KDM4EMAPK1HSD17B10TSHR | |
| SCHEMBL532926 | 0.78 | PIK3CA (0.74) | ALDH1A1KDM4EMAPK1HSD17B10TSHR | |
| SCHEMBL532476 | 0.78 | PIK3CA (0.59) | ALDH1A1KDM4EMAPK1HSD17B10TSHR | |
| SCHEMBL2120634 | 0.77 | PIK3CA (0.58) | ALDH1A1KDM4EMAPK1HSD17B10TSHR | |
| SCHEMBL532154 | 0.77 | KDM4E (0.56) | ALDH1A1KDM4EMAPK1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414369-B1 | IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-12 | — | — | EP | disclosed |
| US-8815918-B2 | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-08-26 | — | — | US | disclosed |
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-19 | — | — | US | disclosed |
| EP-2414369-A1 | IMIDAZO [2, 1-B][ 1, 3, 4]THIADIAZOLE DERIVATIVES | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010112874-A1 | IMIDAZO [2, 1-B] [ 1, 3, 4 ] THIADIAZOLE DERIVATIVES | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | PIK3CA, PI4KA, PIK3CD | ALDH1A1 1167/4885KDM4E 2479/4885MAPK1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.